ClinicalTrials.gg
CompletedNCT06329141Updated Jul 8, 2026

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

A Phase 2 interventional study of Vutiglabridin and Placebo in Parkinson Disease, sponsored by Glaceum. Completed at 9 sites in South Korea. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Glaceum · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies in Parkinson Disease with a site in Korea, Republic of — 13 open to participants now, 15 under way, 1 of them phase 3. Parkinson Disease · Korea, Republic of.

Enrollment
20th of 67
99 · median 60
Started
2024
with 2 others
Phase 2
7 of 76
none open now
Registered
66th of 76
by date

Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 66th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

13 of the 76 studies in Parkinson Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Parkinson Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

  1. Study Objective

    - To assess the efficacy and safety of vutiglabridin in early Parkindson's disease patients

  2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in early Parkinson's disease patients.
  3. Study Design and Protocol This study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based on the inclusion/exclusion criteria will be assigned a subject number and randomized to one of the 3 treatment groups - 1 group receiving a placebo - in a 1:1:1 ratio. Subjects will be randomized to double-blind treatments and will receive a once-daily oral dose of the investigational product for 24 weeks according to the study protocol. Several parameters (i.e., MDS-UPDRS, CGI-C, K-NMSS, modified Hoehn-Yahr stage and SNBR) will be evaluated to assess the efficacy of vutiglabridin. Assessments including measurement of vital signs, 12-lead ECG, clinical laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed to evaluate the safety and tolerability of vutiglabridin. Blood samples will be collected for pharmacokinetic assessment.
03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to read, understand, and provide written consent for the trial, comply with the clinical trial protocol, and communicate any adverse events (AEs) and other information to the investigator (able to complete the evaluation, including walking or using walking aids).
  2. Adult men and women between the ages of 40 and 75 at Screening.
  3. Diagnosed with Parkinson's disease according to the UK Parkinson's Disease Society (UKPDS) Brain Bank clinical diagnostic criteria and confirmed the reduction of dopamine transporter on 18F-FP-CIT PET imaging at Screening.
  4. Diagnosed with Parkinson's disease within the last 24 months.
  5. Hoehn-Yahr stage ≤ 2
  6. Eligible females will be:

    • females of who are not pregnant, evidenced by a negative serum hCG pregnancy test at Screening
    • non-lactating, or
    • surgically sterile (defined as documented bilateral tubal ligation, bilateral tubal occlusion, bilateral oophorectomy, hysterectomy) or .

      • Definition of menopause
    • 50 years or over: 12 or more consecutive months without menstruation, in the absence of other conditions.
    • Less than 50 years: FSH level is > 40 IU/L and 12 or more consecutive months without menstruation, in the absence of other conditions.

Exclusion criteria

Exclusion Criteria:

  1. new illness, per Investigator judgment, in the 4 weeks before Screening and during the screening period.
  2. Global Deterioration Scale (GDS) ≥ 4 at Screening.
  3. Have clinically significant depression as indicated by a Korean Beck Depression Inventory II score (K-BDI-II) > 18 at Screening.
  4. less than 18.5 kg/m2 at Screening.
  5. Have the following laboratory test results:

    • Clinically significant abnormal hepatic (i.e., or ALT greater than 2.5x , or total greater than 2x ULN, unless documented Gilbert's syndrome)
    • Renal function laboratory test (i.e., \< 60 mL/min).
  6. Have the following medical history:

    • Diagnosed with or suspected to have *Parkinson-plus syndromes (PPS)

      • PPS: Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Diffuse Lewy Body Disease, etc.
    • Tremor-dominant Parkinson's disease, per Investigator judgment.
    • Symptoms or signs indicative of neurological functional impairment or known abnormalities in brain CT or MRI imaging.
    • A history of severe heart failure ( class III \~ IV), stroke, cerebral ischemic attacks, or seizures within the past year before screening; or those with a history of myocardial infarction or unstable angina within the last 6 months before screening.
    • Have undergone surgery for Parkinson's disease treatment (e.g., pallidotomy, deep brain stimulation, fetal tissue transplantation) or any other major brain surgery.
    • Diagnosed with malignant tumors within the past 5 years before screening (except for adequately treated basal cell carcinoma, cervical intraepithelial neoplasia, thyroid cancer, or flat epithelial atypia).
    • Diagnosed with secondary Parkinsonism (drug-induced Parkinsonism, normal pressure hydrocephalus, vascular Parkinsonism).
  7. Have swallowing problems
  8. Have clinically significant dizziness, nausea, per Investigator's judgment.
  9. Currently taking any of the following medications and have the willingness and ability to continue taking them throughout the clinical trial period:

    • Within the 4 weeks before baseline, taking any Parkinson's disease medications, including dopamine agonists, dopamine-depleting enzyme inhibitors [monoamine oxidase inhibitors (MAOi), COMT (catechol-O-methyltransferase) inhibitors], non-dopaminergic drugs (anticholinergic agents, amantadine, etc.), and others PD medications (In case of irreversible MAO-B inhibitor, within the 90 days before baseline)
    • Within the 12 weeks before screening, have used systemic continuously for 7 days or longer.
    • Within the 12 weeks before baseline, taking levodopa or levodopa combinations (including history of levodopa use for more than 4 weeks)
    • Currently taking medications known to be substrates of breast cancer resistant protein (BCRP) at screening (e.g., rosuvastatin, serpalan, etc.) (Note: If switched to another drug of the same class, the subject may be eligible for inclusion).
    • taking of any medication within 6 months of Screening that can alter reproductive hormone levels, either as the intended effect or as a side effect, including: anabolic steroids, androstenedione, bicalutamide, cimetidine, dehydroepiandrosterone, diethylstilbestrol, other estrogens, dutasteride, finasteride, glucocorticoids (e.g., prednisone, cortisone, hydrocortisone, and decadron), oral ketoconazole, megestrol acetate, opiates (e.g., morphine, codeine, oxycodone, hydrocodone), spironolactone, testosterone or any androgen, and any medications for treating prostate cancer.
  10. Have taken of stable doses of levodopa or levodopa combination
  11. Have known or suspected intolerance to PET scan or fluoropropyl-CIT (18F).
  12. Have a history of organ transplantation.
  13. Tested positive for , Ab, Ag/Ab, or VDRL(RPR) antibodies in screening tests.
  14. Known or to the main ingredient and of the product.
  15. Anticipated to undergo surgery during the clinical trial period or to receive surgical interventions that may affect the completion of the trial or compliance with the clinical trial protocol.
  16. Participated in a clinical trial for an investigational drug or medical device for a period equal to or longer than five times the drug's half-life at baseline or within the past 12 weeks, whichever is longer.
  17. Unwilling, or whose partner is unwilling, to use a medically acceptable means of * during and for 90 days following completion/withdrawal of the study.

    • Medically acceptable contraceptive methods include:

      • intrauterine device that has been proven highly effective, used by the subject or the subject's spouse/partner
      • physical contraception (male or female) used with chemical sterilization surgical sterilization of the subject or the subject's partner (e.g., vasectomy, hysterectomy, tubal ligation, salpingectomy
      • oral hormonal contraceptive used by the spouse/partner of male subject.
  18. Within the last 2 years before screening or during the screening period, have a history of alcohol or drug abuse, or have tested positive for drug use during the screening period (Note: Subjects who have used drugs for the purpose of chronic pain treatment, have documented records of medical history and concomitant medications, may, at the investigator's discretion and with the sponsor's approval, be eligible for inclusion as trial subjects).
  19. Deemed unsuitable for participation in the clinical trial by the investigator due to reasons including clinical laboratory test results and other factors.
  20. Participating in a non-interventional clinical study that may affect the safety or efficacy assessment of subjects in this clinical trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Vutiglabridin 400 mg Multiple Dose

    Multiple oral dosing of vutiglabridin 400 mg for 24 weeks

    Drug: Vutiglabridin

  • Experimental
    Vutiglabridin 800 mg Multiple Dose

    Multiple oral dosing of vutiglabridin 800 mg for 24 weeks

    Drug: Vutiglabridin

  • Placebo comparator
    Placebo

    Multiple oral dosing of placebo

    Drug: Placebo

Interventions

  • DrugVutiglabridin

    Once-daily oral administration

    Also known as: HSG4112, 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol

  • DrugPlacebo

    Once-daily oral administration

06

What researchers measure

Primary outcomes

  1. Change From Baseline in MDS-UPDRS Part III Subscore

    Time frame: From baseline to Week 24

Secondary outcomes

  1. Change From Baseline in MDS-UPDRS Part III Subscore

    Time frame: From baseline to Week 4, Week 12, Week 28

  2. Change From Baseline in MDS-UPDRS Part II + Part III

    Time frame: From baseline to Week 4, Week 12, Week 28

  3. Change From Baseline in CGI-C score

    Time frame: From baseline to Week 4, Week 12, Week 24

  4. Change From Baseline in K-NMSS score

    Time frame: From baseline to Week 4, Week 24

  5. Change From Baseline in Modified Hoehn-Yahr stage

    Time frame: From baseline to Week 4, Week 12, Week 24

  6. Change From Baseline in PET SNBR (Specific to Non-specific Binding Ratio) in the putamen, acudate and nucleus

    Time frame: From baseline to Week 24

  7. Drop-out rate due to taking anti-parkinson drug

    Time frame: From baseline to Week 28 (follow-up visit)

07

Study locations

9 sites
  • Hallym University Medical Center
    Anyang-si, Gyeonggi-do 14068, South Korea
  • The Catholic University of Korea Uijeongbu St.Marys Hostpial
    Uijeongbu-si, Gyeonggi-do 11765, South Korea
  • Inje University Busan Paik Hospital
    Busan, 47392, South Korea
  • Inje University Sanggye Paik Hospital
    Seoul, 01757, South Korea
  • KyungHee University Medical Center
    Seoul, 02447, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • The Catholic University of Korea
    Seoul, 06591, South Korea
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Dec 2025, 16 months.

Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Mar 25, 2024
StartActual
Jul 22, 2024
Primary completionActual
Dec 16, 2025
CompletionActual
Jan 7, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06329141
Lead sponsor
Glaceum
Collaborators
Kyunghee University Medical Center, Korea University Guro Hospital, Samsung Medical Center, Severance Hospital, Inje University, Hallym University Medical Center, The Catholic University of Korea, Uijeongbu St. Mary Hospital
Responsible party
Sponsor
First posted
Mar 25, 2024
Start date
Jul 22, 2024
Primary completion
Dec 16, 2025
Completion
Jan 7, 2026
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion